Antifibrinolytics in Massive Transfusion
Antifibrinolytic agents, such as tranexamic acid (TXA), play a key role in massive transfusion by reducing blood loss by inhibiting fibrinolysis. TXA is particularly effective when administered early, within three hours of trauma or bleeding onset, and is associated with improved survival outcomes.
Calcium Supplementation
Calcium supplementation is often necessary, given the risk of citrate-induced hypocalcemia during massive transfusion. Anesthesia providers should monitor ionized calcium levels and administer calcium gluconate or calcium chloride as needed to prevent cardiac and coagulation dysfunction.
Vasopressors and Inotropes
In hemorrhagic shock, vasopressors (e.g., norepinephrine) may be required to maintain perfusion pressure, especially when fluid resuscitation alone is insufficient. Inotropes like dobutamine may be used to support myocardial contractility. However, these agents should be used cautiously, as they can exacerbate tissue hypoxia if used without adequate volume resuscitation.
| Agent | Role | Key consideration |
|---|---|---|
| Tranexamic acid (TXA) | Antifibrinolytic that reduces blood loss by inhibiting fibrinolysis | Most effective given early, within three hours of trauma or bleeding onset, and associated with improved survival |
| Calcium gluconate or calcium chloride | Corrects citrate-induced hypocalcemia during massive transfusion | Monitor ionized calcium and supplement as needed to prevent cardiac and coagulation dysfunction |
| Vasopressors (e.g., norepinephrine) | Maintain perfusion pressure in hemorrhagic shock when fluid resuscitation alone is insufficient | Use cautiously; can worsen tissue hypoxia without adequate volume resuscitation |
| Inotropes (e.g., dobutamine) | Support myocardial contractility | Same caution — hypoxia may be exacerbated if given without adequate volume resuscitation |
